Current and historical daily PE Ratio for XNCR (
Xencor Inc
) from 2013 to Dec 02 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Xencor stock (XNCR) PE ratio as of Dec 02 2023 is 0.
More Details
Xencor Inc (XNCR) PE Ratio (TTM) Chart
Xencor Inc (XNCR) PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Total 1241
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Xencor PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2023-12-02 | At Loss | 2023-09-28 | At Loss |
| 2023-11-30 | At Loss | 2023-09-27 | At Loss |
| 2023-11-29 | At Loss | 2023-09-26 | At Loss |
| 2023-11-28 | At Loss | 2023-09-25 | At Loss |
| 2023-11-27 | At Loss | 2023-09-22 | At Loss |
| 2023-11-24 | At Loss | 2023-09-21 | At Loss |
| 2023-11-22 | At Loss | 2023-09-20 | At Loss |
| 2023-11-21 | At Loss | 2023-09-19 | At Loss |
| 2023-11-20 | At Loss | 2023-09-18 | At Loss |
| 2023-11-17 | At Loss | 2023-09-15 | At Loss |
| 2023-11-16 | At Loss | 2023-09-14 | At Loss |
| 2023-11-15 | At Loss | 2023-09-13 | At Loss |
| 2023-11-14 | At Loss | 2023-09-12 | At Loss |
| 2023-11-13 | At Loss | 2023-09-11 | At Loss |
| 2023-11-10 | At Loss | 2023-09-08 | At Loss |
| 2023-11-09 | At Loss | 2023-09-07 | At Loss |
| 2023-11-08 | At Loss | 2023-09-06 | At Loss |
| 2023-11-07 | At Loss | 2023-09-05 | At Loss |
| 2023-11-06 | At Loss | 2023-09-01 | At Loss |
| 2023-11-03 | At Loss | 2023-08-31 | At Loss |
| 2023-11-02 | At Loss | 2023-08-30 | At Loss |
| 2023-11-01 | At Loss | 2023-08-29 | At Loss |
| 2023-10-31 | At Loss | 2023-08-28 | At Loss |
| 2023-10-30 | At Loss | 2023-08-25 | At Loss |
| 2023-10-27 | At Loss | 2023-08-24 | At Loss |
| 2023-10-26 | At Loss | 2023-08-23 | At Loss |
| 2023-10-25 | At Loss | 2023-08-22 | At Loss |
| 2023-10-24 | At Loss | 2023-08-21 | At Loss |
| 2023-10-23 | At Loss | 2023-08-18 | At Loss |
| 2023-10-20 | At Loss | 2023-08-17 | At Loss |
| 2023-10-19 | At Loss | 2023-08-16 | At Loss |
| 2023-10-18 | At Loss | 2023-08-15 | At Loss |
| 2023-10-17 | At Loss | 2023-08-14 | At Loss |
| 2023-10-16 | At Loss | 2023-08-11 | At Loss |
| 2023-10-13 | At Loss | 2023-08-10 | At Loss |
| 2023-10-12 | At Loss | 2023-08-09 | At Loss |
| 2023-10-11 | At Loss | 2023-08-08 | At Loss |
| 2023-10-10 | At Loss | 2023-08-07 | At Loss |
| 2023-10-09 | At Loss | 2023-08-04 | At Loss |
| 2023-10-06 | At Loss | 2023-08-03 | At Loss |
| 2023-10-05 | At Loss | 2023-08-02 | At Loss |
| 2023-10-04 | At Loss | 2023-08-01 | At Loss |
| 2023-10-03 | At Loss | 2023-07-31 | At Loss |
| 2023-10-02 | At Loss | 2023-07-28 | At Loss |
| 2023-09-29 | At Loss | 2023-07-27 | At Loss |
Xencor Inc (XNCR) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Xencor Inc
NAICS : 325412
SIC : 2834
ISIN : US98401F1057
Description
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers